Jefferies analyst Benjamin Jackson CFA has maintained their bullish stance on GALD stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that suggest Galderma Group AG is well-positioned for future growth despite potential challenges. The analysis indicates that the market is currently factoring in a significant growth slowdown for 2025-2026 in consumer-sensitive categories, which may not fully materialize, presenting an opportunity for upside.
Furthermore, the expected direct and indirect impacts on earnings per share (EPS) from potential tariffs on US Fillers, Biostimulators, and other pharmaceutical products have been thoroughly assessed. The stress tests conducted show that even with these potential tariff impacts, Galderma Group AG’s financial performance remains robust, supporting the Buy recommendation.
Jackson CFA covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Sanofi, and ALK-abello. According to TipRanks, Jackson CFA has an average return of -19.9% and a 27.27% success rate on recommended stocks.
In another report released today, Goldman Sachs also reiterated a Buy rating on the stock with a $0.00 price target.